Basal Plus Basal–Bolus Approach in Type 2 Diabetes
Open Access
- 1 June 2011
- journal article
- research article
- Published by SAGE Publications in Diabetes Technology & Therapeutics
- Vol. 13 (1_suppl) , S75-83
Abstract
Type 2 diabetes is characterized by insulin resistance and progressive β -cell deterioration. As β -cell function declines, most patients with type 2 diabetes treated with oral agents, in monotherapy or combination, will require insulin therapy. Addition of basal insulin (glargine, detemir, or NPH/neutral protamine lispro insulin) to previous treatment is accepted as the simplest way to start insulin therapy in those patients. But even when basal insulin is adequately titrated, some patients will also need prandial insulin to achieve or maintain individual glycemic targets over time. Starting with premixed insulin is an effective option, but it is frequently associated with increased hypoglycemia risk, fixed meal schedules, and weight gain. As an alternative, a novel approached known as “basal plus strategy” has been developed. This approach considers the addition of increasing injections of prandial insulin, beginning with the meal that has the major impact on postprandial glucose values. Finally, if this is not enough intensification to basal–bolus will be necessary. In reducing hyperglycemia, this modality still remains the most effective option, even in people with type 2 diabetes. This article will review the currently evidence on the basal plus strategy and also its progression to basal–bolus therapy. In addition, practical recommendations to start and adjust basal plus therapy will be provided.Keywords
This publication has 62 references indexed in Scilit:
- Is Glycemic Control Improving in U.S. Adults?Diabetes Care, 2008
- A 26-Week, Randomized, Parallel, Treat-to-Target Trial Comparing Insulin Detemir With NPH Insulin as Add-On Therapy to Oral Glucose-Lowering Drugs in Insulin-Naïve People With Type 2 DiabetesDiabetes Care, 2006
- Making the transition from oral to insulin therapyThe American Journal of Medicine, 2005
- The Treat-to-Target TrialDiabetes Care, 2003
- Glycemic Control With Diet, Sulfonylurea, Metformin, or Insulin in Patients With Type 2 Diabetes MellitusProgressive Requirement for Multiple Therapies (UKPDS 49)JAMA, 1999
- Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)The Lancet, 1998
- U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study GroupDiabetes, 1995
- Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year studyDiabetes Research and Clinical Practice, 1995
- The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes MellitusNew England Journal of Medicine, 1993
- Comparison of Insulin Regimens in Patients with Non-Insulin-Dependent Diabetes MellitusNew England Journal of Medicine, 1992